Authors:
Hilgeroth, A
Fleischer, R
Wiese, M
Heinemann, FW
Citation: A. Hilgeroth et al., Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cagedimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representativeof a novel class of HIV-1 protease inhibitors: A molecular modeling study, J COMPUT A, 13(3), 1999, pp. 233-242
Citation: G. Shlieout et al., A new method to evaluate the consolidation behavior of pharmaceutical materials by using the Fraser-Suzuki function, DRUG DEV IN, 25(1), 1999, pp. 29-36
Authors:
Rispeter, K
Lu, MJ
Zibert, A
Wiese, M
de Oliveira, JM
Roggendorf, M
Citation: K. Rispeter et al., A suggested extension of the HCVISDR does not alter our former conclusionson its predictive value for IFN response, J HEPATOL, 30(6), 1999, pp. 1163-1164
Citation: M. Wiese et al., Expression and species-specific glycosylation of Leishmania mexicana secreted acid phosphatase in Leishmania major, MOL BIOCH P, 102(2), 1999, pp. 325-329
Citation: Mj. Lu et al., Selection of genetic variants of the 5 ' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy, J MED VIROL, 59(2), 1999, pp. 146-153
Citation: U. Franke et al., Ionization constants and distribution coefficients of phenothiazines and calcium channel antagonists determined by a pH-metric method and correlationwith calculated partition coefficients, J PHARM SCI, 88(1), 1999, pp. 89-95
Citation: A. Hilgeroth et al., Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors, J MED CHEM, 42(22), 1999, pp. 4729-4732
Authors:
Musch, E
Hogemann, B
Gerritzen, A
Fischer, HP
Wiese, M
Kruis, W
Malek, M
Gugler, R
Schmidt, G
Huchzermeyer, H
Gerlach, U
Dengler, HJ
Sauerbach, T
Citation: E. Musch et al., Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B, HEP-GASTRO, 45(24), 1998, pp. 2282-2294